This approach is routinely utilized at USAMRIID to study the
development of viral
therapeutic resistance against
antiviral countermeasures, according to Dr. Gustavo Palacios, director of the center and senior author of the study.
Their results, the researchers conclude, «show that computationally designed proteins have potent anti-viral efficacy in vivo and suggests promise for
development of a new class of HA stem - targeted
antivirals for both
therapeutic and prophylactic protection against seasonal and emerging strains of influenza.»